AI Science Tracker

University of Illinois Urbana-Champaign

6 discoveries from 2021 to 2025

Discoveries

A closed-loop platform engineers enzymes with minimal human input

The July 2025 Nature Communications paper reports AI-guided biofoundry engineering of two enzymes in four rounds over four weeks, testing fewer than 500 variants per enzyme. Different AtHMT variants achieved about 90-fold greater ethyl-iodide substrate preference and 16-fold ethyltransferase activity; YmPhytase activity improved 26-fold at neutral pH. The system combines ML variant selection, language-model access and automated experiments; the authors describe conditional-to-high automation.

Technology: Machine learning and LLM-guided variant design with biofoundry automation

Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: direct test
  • Tested: Enzyme activity and purified-variant kinetic measurements in two campaigns.
  • Still unknown: Not assessed: supplements; broad applicability beyond two enzymes. Authors classify automation between levels 3 and 4.
  • AI role: Protein models and regression selected variants; the biofoundry built and tested them.

Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC12215622/

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: linked separately.

Review scope and date are not recorded; source checked does not establish full-text review.

Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 140 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.

Editorial assessment: Impact 4/5 · Validation 3/5 · Novelty 4/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

LAISS-assisted review reclassifies anomalous ZTF transients

Expert review of 455 previously observed transients changed 16 normal labels to anomalous; the random-forest model flagged 11 of these. Spectra, light curves and host context supported the reclassifications. This is a retrospective study-level result rather than a count of newly observed events or newly established physical classes. Human review and similarity searches also contributed, so the entire retrospective sample is not attributed to the classifier.

Technology: LAISS random-forest anomaly classifier and similarity search

Publication: Preprint · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Preprint
  • Test type: retrospective or benchmark
  • Tested: Existing photometry and classification spectra were re-examined to support revised labels.
  • Still unknown: Anomaly categories depend on expert judgments; universal first-discovery priority and new physical mechanisms are not established.
  • AI role: LAISS random-forest anomaly classifier and similarity search supported the stated study; experimental and interpretive work remained with researchers.

Evidence sources: https://arxiv.org/abs/2404.01235v1 · https://arxiv.org/html/2404.01235v1

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: linked separately.

Review date: 16 Nov 2026. Review scope: Primary arXiv v1 HTML abstract, selected classifier/reclassification Results and affiliations; version history checked..

Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

BacterAI experimentally maps amino-acid growth requirements of two oral Streptococcus species

BacterAI autonomously designed and ran growth experiments with robotic liquid handling to learn amino-acid requirements for the oral commensals Streptococcus gordonii and S. sanguinis. It learned separate growth rules for each organism and showed that the closely related species have different amino-acid auxotrophies. For S. gordonii, its neural-network growth predictions exceeded 90% accuracy after nine days and 3,024 experiments; the article also reports transfer-learning tests in larger media.

Technology: BacterAI, a reinforcement-learning agent coupled to iterative neural-network growth models and automated laboratory robots

Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: direct test
  • Tested: BacterAI autonomously designed and ran growth experiments with robotic liquid handling to learn amino-acid requirements for the oral commensals Streptococcus gordonii and S. sanguinis.
  • Still unknown: The measured outcomes are in defined growth media under the tested laboratory conditions, not direct evidence about nutrient exchange or health effects in a human oral microbiome. The article establishes that the two species have different amino-acid requirements; transfer learning and high growth-prediction accuracy describe the method’s performance, not separate biological discoveries. Replicate growth assays showed high agreement, but inferred rules may not cover every environmental condition.
  • AI role: The agent selected successive combinations of amino acids to test based on prior growth results, executed those tests through an automated pipeline, and distilled results into interpretable growth rules. It enabled an unbiased experimental mapping of nutrient requirements from a blank slate for both species.

Evidence sources: https://www.nature.com/articles/s41564-023-01376-0

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: linked separately.

Review scope and date are not recorded; source checked does not establish full-text review.

Citations: in the top 10% of works of the same type, year and subfield (OpenAlex work metrics, 52 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.

Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

CLEAN experimentally identifies SAM hydrolase activity in previously uncharacterized proteins

Researchers at the University of Illinois Urbana–Champaign developed CLEAN, a contrastive-learning enzyme-function predictor, and used it to identify the SAM hydrolase activity of the previously uncharacterized protein TTHA0338. In vitro HPLC–MS and enzyme-kinetic experiments also corrected the annotation of MJ1651 and confirmed the multiple activities of SsFIA.

Technology: CLEAN (contrastive learning-based enzyme annotation model)

Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: direct test
  • Tested: In vitro HPLC–MS and enzyme-kinetic experiments also corrected the annotation of MJ1651 and confirmed the multiple activities of SsFIA.
  • Still unknown: The study validated a small, selected set of proteins, and also showed CLEAN can assign functions to non-enzymes; the demonstrated result is specific to the tested proteins. TTHA0338 is one of multiple results reported by this paper; record describes the previously unknown function rather than treating every model benchmark as a separate discovery.
  • AI role: CLEAN predicted enzyme commission functions from protein sequences; researchers then validated the predicted activity experimentally. It was the model that nominated TTHA0338 as a SAM hydrolase, not an autonomous discovery or validation system.

Evidence sources: https://doi.org/10.1126/science.adf2465

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.

Review scope and date are not recorded; source checked does not establish full-text review.

Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 482 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.

Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

ECNet-guided selection of higher-order TEM-1 variants

ECNet integrated evolutionary context with learned sequence representations to prioritize previously untested higher-order TEM-1 variants. The authors constructed and measured 37 selected variants under ampicillin selection, using relative resistance as an enzyme-fitness proxy. The assays do not imply clinical treatment outcomes, and the reported group of 37 should not be read as showing that every variant improved.

Technology: ECNet evolutionary-context-integrated deep-learning framework

Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: direct test
  • Tested: Thirty-seven previously untested higher-order TEM-1 variants selected with ECNet were constructed and experimentally measured under ampicillin selection against wild-type and study controls. The study uses relative resistance as an enzyme-fitness proxy.
  • Still unknown: The bounded entry does not imply that all 37 variants improved equally, does not establish clinical outcomes, and makes no claim of independent sequence novelty beyond the authors’ screened literature.
  • AI role: ECNet integrated evolutionary context and a learned representation to prioritize higher-order TEM-1 variants for experimental construction and ampicillin-selection measurements.

Evidence sources: https://www.nature.com/articles/s41467-021-25976-8 · https://zhaogroup.web.illinois.edu/publications/HZ370.pdf

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: linked separately.

Review date: 17 Nov 2026. Review scope: Primary Nature indexed article and author-hosted full text; official bioRxiv API checked and identified the previously associated preprint DOI as a different paper..

Editorial assessment: Impact 2/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

Open the interactive profile for the timeline, or browse all organizations and model families.